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Autophagy is a highly conserved process by which long-lived macromolecules, protein
aggregates and dysfunctional/damaged organelles are delivered to lysosomes for
degradation. Autophagy plays a crucial role in regulating protein quality control and
cell homeostasis in response to energetic needs and environmental challenges.
Indeed, activation of autophagy increases the life-span of living organisms, and
impairment of autophagy is associated with several human disorders, among which
neurodegenerative disorders of aging, such as Parkinson’s disease. These disorders
are characterized by the accumulation of aggregates of aberrant or misfolded proteins
that are toxic for neurons. Since aging is associated with impaired autophagy,
autophagy inducers have been viewed as a strategy to counteract the age-related
physiological decline in brain functions and emergence of neurodegenerative disorders.
Parkinson’s disease is a hypokinetic, multisystemic disorder characterized by age-
related, progressive degeneration of central and peripheral neuronal populations,
associated with intraneuronal accumulation of proteinaceous aggregates mainly
composed by the presynaptic protein α-synuclein. α-synuclein is a substrate of
macroautophagy and chaperone-mediated autophagy (two major forms of autophagy),
thus impairment of its clearance might favor the process of α-synuclein seeding
and spreading that trigger and sustain the progression of this disorder. Genetic
factors causing Parkinson’s disease have been identified, among which mutations in
the LRRK2 gene, which encodes for a multidomain protein encompassing central
GTPase and kinase domains, surrounded by protein-protein interaction domains. Six
LRRK2 mutations have been pathogenically linked to Parkinson’s disease, the most
frequent being the G2019S in the kinase domain. LRRK2-associated Parkinson’s
disease is clinically and neuropathologically similar to idiopathic Parkinson’s disease,
also showing age-dependency and incomplete penetrance. Several mechanisms have
been proposed through which LRRK2 mutations can lead to Parkinson’s disease. The
present article will focus on the evidence that LRRK2 and its mutants are associated
with autophagy dysregulation. Studies in cell lines and neurons in vitro and in LRRK2
knock-out, knock-in, kinase-dead and transgenic animals in vivo will be reviewed.
The role of aging in LRRK2-induced synucleinopathy will be discussed. Possible
mechanisms underlying the LRRK2-mediated control over autophagy will be analyzed,
and the contribution of autophagy dysregulation to the neurotoxic actions of LRRK2 will
be examined.
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INTRODUCTION
Autophagy is a highly conserved cellular degradation process,
either bulk or selective, by which long-lived macromolecules,
protein aggregates and dysfunctional/damaged organelles are
delivered to lysosomes for degradation (Deter et al., 1967;
Mortimore and Schworer, 1977). This constitutive physiological
activity works in parallel with the UPS to implement protein
quality control and maintain the integrity of cell proteome (i.e.,
cellular proteostasis). Recently, the involvement of autophagy
in general energy homeostasis has also been proven, since
autophagy can be stimulated in response to starvation-induced
stress, amino acid depletion as well as cell energy needs (Puente
et al., 2016; Ho et al., 2017; Olsvik et al., 2019; Sutton et al., 2019).
Dysfunctions of the ALP have been reported in aging as
well as in several human disorders, including cancer, chronic
inflammatory diseases, cardiomyopathies and neurodegenerative
diseases (Mizushima et al., 2008; Boland et al., 2018; Deretic and
Klionsky, 2018; Onorati et al., 2018; Zech et al., 2019). Notably,
neurodegenerative disorders of aging such as Parkinson’s disease
(PD), Alzheimer’s disease (AD), Huntington’s disease (HD)
frontotemporal dementia and amyotrophic lateral sclerosis are
characterized by a common feature: accumulation of aberrant or
misfolded proteins, such as α-synuclein (α-syn), Aβ, tau, mutant
forms of huntingtin, TDP43, which are neurotoxic (Gal et al.,
2009; Bourdenx et al., 2017; Boland et al., 2018). Furthermore,
either blocking or promoting autophagy has an impact on
clearance of cytotoxic proteins in different in vitro and in vivo
models of aggregopathies/proteinopathies (Sarkar et al., 2008;
Crews et al., 2010; Spilman et al., 2010; Ciechanover and Kwon,
2017; Moors et al., 2017).
THE AUTHOPHAGY-LYSOSOMAL
PATHWAY
Macroautophagy, CMA and microautophagy are the three major
forms of autophagy identified so far, although other forms such
Abbreviations: 4E-BP, eukaryotic initiation factor 4E binding protein; α-syn: α-
synuclein; AD, Alzheimer’s disease; ALP, autophagy-lysosomes pathway; AMPK,
5′-AMP-activated kinase; ATG, autophagy-related gene 8; AV, autophagic vacuoles;
Aβ, β amyloid; CMA, chaperone-mediated autophagy; CNS, central nervous
system; COR, C-terminal of Roc; DA, dopamine; DAMPs, damage-associated
molecular patterns; DKO, double knock-out; DLB, dementia with Lewy bodies;
eIF4E, eukaryotic initiation factor 4E; EM, electron microscopy; ER, endoplasmic
reticulum; ESCRT, endosomal sorting complexes required for transport; GCase,
β-glucocerebrosidase; HD, Huntington’s disease; Hsc70/HSPA8, heat shock 70
kDa protein 8; IGF-1, insulin growth factor-1; KD, kinase dead; KI, knock-in;
KO, knock-out; LAMP1, lysosome-associated membrane protein 1; LAMP2A,
lysosome-associated membrane protein 2 isoform A; LBs, Lewy bodies; LC3I,
microtubule-associated protein 1 light chain 3 beta isoform 1; LC3II, microtubule-
associated protein 1 light chain 3 beta isoform 2; LIR, LC3-interacting region;
LRRK1, leucine-rich repeat kinase 1; LRRK2, leucine-rich repeat kinase 2; mtDNA,
mitochondrial DNA; mTORC1, mammalian target of rapamycin complex 1;
MVBs, multivesicular bodies; NFE2L2/NRF2, nuclear factor, erythroid derived
2, like 2; PD, Parkinson’s Disease; PINK1, PTEN-induced putative kinase 1;
ROC, Ras of complex; ROS, reactive oxygen species; SNpc, substantia nigra
pars compacta; SQSTM1/p62, Sequestosome 1; TDP43, TAR DNA-binding
protein 43; TFEB, transcription factor EB; TRIM, tripartite motif protein family;
UBA, ubiquitin-associated domain; ULK1, uncoordinated-51-like kinase 1; UPS,
ubiquitin-proteasome system; VPS34, vacuolar protein sorting 34.
as selective and precision autophagy have been described more
recently (Klionsky, 2005; Massey et al., 2006; Kimura et al.,
2015; Dikic, 2017). Macroautophagy (henceforth referred to
as autophagy) requires autophagosome biogenesis, a complex
multi-step process regulated by the autophagy-related (ATG)
gene family member proteins (Tsukada and Ohsumi, 1993;
Thumm et al., 1994; Klionsky et al., 2003; Klionsky, 2012),
whose transcription is driven by TFEB (Settembre et al., 2011)
and many other transcription factors, such as FOXOs, E2F1,
CREB, PPARγ to name a few (Fullgrabe et al., 2016). ATGs
protein activity is controlled upstream by nutrient and growth
signaling pathways. Autophagy starts with the formation of an
isolation cup-shaped membrane (also termed phagophore) that
elongates and sequesters a small portion of the cytoplasm to
form the autophagosome (Figure 1). Then, the autophagosome
fuses to the lysosomes, generating autolysosomes. Selective
cargo recognition and sequestration into the autophagosome
lumen require the presence of receptor-proteins, among which
microtubule-associated protein 1 light chain 3 (known as
MAP1LC3 or LC3). The cytosolic form of LC3, LC3I, translocates
to the autophagosome membranes after being conjugated to
phosphatidylethanolamine (Stolz et al., 2014; Rockenfeller et al.,
2015). The abundance of LC3II, i.e., the lipidated form of LC3I, is
directly correlated with the number of mature autophagosomes.
LC3II partners in cargo recognition and delivery to lysosomes
are a number of selective-autophagy receptor proteins such as
Sequestosome 1 (SQSTM1)/p62 and other sequestosome 1-like
receptors (NBR1, optineurin, NDP52, TAX1BP1, TOLLIP and
ALFY/WDFY3) (Conway et al., 2019). p62, the first autophagy
adaptor protein to be identified (Ishii et al., 1996), recognizes
ubiquitinated proteins via its ubiquitin-associated (UBA) domain
and docks onto the forming phagophore membrane through
binding LC3II via the LC3-interacting region (LIR). Impaired
autophagy leads to SQSTM1/p62 accumulation and aggregation
of ubiquitinated proteins (Komatsu et al., 2007a). LC3I, LC3II,
SQSTM1/p62 and mTOR are all validated markers of autophagy
(Brown et al., 1994; Sugawara et al., 2004; Lippai and Low, 2014).
Mammalian target of rapamycin complex 1 (mTORC1) and 5′-
AMP-activated kinase (AMPK) act as key upstream regulators of
autophagy by modulating the serine-threonine kinase activity of
ULK1/2. Upon activation, ULK1 phosphorylates and associates
with ATG101, focal adhesion kinase family interacting protein
of 200 kDa (FIP200) and ATG13 (Hara et al., 2008; Chan, 2009;
Ganley et al., 2009) to generate the Initiation Complex. This
complex acts as cellular sensor for glucose, nitrogen, growth
factors, amino acids and ROS concentrations (Kim and Guan,
2015). In the presence of high levels of nutrients, mTORC1 acts
as an inhibitor of autophagy by directly hyperphosphorylating
ATG13 and ULK1 (at Ser757), which prevents ULK1 binding to
ATG13 and AMPK (Kim and Guan, 2015; Meijer et al., 2015).
Conversely, amino acids depletion suppresses mTORC1 activity.
Furthermore, there is evidence that under glucose starvation
or increased AMP/ATP ratio, AMPK negatively modulates
mTORC1 pathway, phosphorylating (at Ser317 and Ser777)
and activating ULK1 (Kim et al., 2011). Interestingly, recent
studies have shown that amino acid and glucose depletion
promote autophagy with different efficiencies. Indeed, amino
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FIGURE 1 | The autophagic machinery. Three types of autophagy have been described: macroautophagy (henceforth referred to as autophagy),
chaperone-mediated autophagy (CMA) and microautophagy. Autophagy is positively regulated by AMPK and negatively by mTORC1 which, in turn phosphorylates
and mediates ULK1-initiation complex association and activation. The ATGs protein family, organized in three major complexes (the ULK1-initiation complex, PI3K III
nucleation complex and PI3P-binding complex), mediates the formation of a cup-shaped membrane, termed phagophore. The phagophore directly engulfs a small
portion of cytoplasm containing damaged organelles, misfolded or old proteins to form the autophagosome. Then, the autophagosome fuses with the lysosome,
generating the autolysosome, in which autophagic substrates are degraded by lysosomal hydrolases activity and acidic environment. Substrate recognition and
sequestration can also occur in a selective manner through intervention of LC3II. LC3I is a cytosolic protein, which after being conjugated to PE, translocates onto
the phagophore membranes where it acts as a receptor for multiple cargo proteins, such as p62. p62 binds both LC3II (LIR domain) and ubiquitinated proteins (UBA
domain), allowing their entry into the autophagosome for degradation. CMA is a one-by-one fashion type of autophagy and it is only referred to proteins bearing the
KFERQ-like motif. Those proteins are directly recognized by cytosolic Hsc70, which shuttles them to the lysosomal membrane where it binds LAMP2A, a
transmembrane receptor. The binding of Hsc70 to LAMP2A leads to its oligomerization, promoting the entry of CMA substrates into the lysosomal lumen. The
presence of lysosomal Hsc70 is also required for cargo sequestration. Microautophagy is the least characterized form of autophagy. During microautophagy,
substrates are directly engulfed by the lysosomal membrane, without an intermediate autophagosome formation.
acid starvation is able to induce ULK1-initiation complex
formation and promote a great amount of autophagosomes
containing LC3II and p62 whereas glucose starvation does not
(Nwadike et al., 2018). In addition, amino acid but not glucose
depletion, leads to lysosomal acidification, independently from
autophagy and ULK1 (Nwadike et al., 2018). Furthermore, there
is evidence of mTORC1 activation in a lysosomal nutrient
sensing-dependent manner. In fact, amino acid depletion
prevents mTORC1 recruitment and activation on the lysosomal
membrane via AMPK-independent mechanisms, operated by
the Rag GTPase complex, that recruits mTORC1, and by Rheb,
that activates it (Lim and Zoncu, 2016). Once translocated
on the lysosomal membrane, mTORC1 directly controls the
subcellular localization of TFEB, a master autophagy regulator
which continuously shuttles from the cytosol to the nucleus,
where it mediates ATGs transcription and lysosomal biogenesis
under starvation conditions (Sardiello et al., 2009; Settembre
et al., 2011). mTORC1 phosphorylates TFEB in the nucleus and
controls its export kinetics in a nutrient availability dependent
manner (Napolitano et al., 2018). However, TFEB is able to
promote autophagy gene expression not only during starvation
but also during mitochondria depolarization (Nezich et al.,
2015), ER stress (Martina et al., 2016) or lysosomal membrane
permeabilization (Settembre et al., 2012).
CMA (Figure 1) is a one-by-one fashion-type of autophagy.
About 30% of cytosolic proteins bear the Lys-Phe-Glu-Arg-Gln
(KFERQ) sequence (Dice et al., 1986; Chiang and Dice, 1988;
Chiang et al., 1989) which is recognized by cytosolic heat shock
70 kDa protein 8 (HSPA8, also known as hsc70). Then, hsc70,
complexed with co-chaperones, shuttles the substrate proteins
to the lysosomal membrane, where it binds to monomeric
LAMP2A, a transmembrane receptor. This binding triggers
LAMP2A multimerization into a translocation complex. Protein
substrates must be unfolded by hsc70 and co-chaperones, and
luminal hsc70 is also required to allow their translocation
to the lysosomal lumen, where they are quickly hydrolyzed.
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Considering that the binding to LAMP2A is the rate-limiting
step for CMA and that LAMP2A-deficient lysosomes are CMA-
incompetent (Cuervo et al., 1997; Kaushik and Cuervo, 2012),
LAMP2A is considered a marker of CMA. In particular, LAMP2A
subcellular localization has been associated with Rab11 and
Rab7 function (Zhang et al., 2017). The signaling pathways that
mediate the upstream modulation of CMA are still not fully
understood, however, a possible crosstalk between CMA and
redox stress has been proposed via NFE2L2/NRF2 (nuclear factor,
erythroid derived 2, like 2) (Pajares et al., 2018). Furthermore,
oxidized proteins, such as Tau and α-syn are CMA substrates
(Xilouri and Stefanis, 2015; Dikic, 2017).
Microautophagy (Figure 1) and endosomal microautophagy
are the least characterized types of autophagy. Microautophagy
is a constitutive active process by which cytoplasmic content
is directly engulfed into lysosomes for degradation, without an
intermediate autophagosome formation (Farre and Subramani,
2004). Instead, endosomal microautophagy occurs at the surface
of late endosomes following the formation of multivesicular
bodies (MVBs), that ultimately fuse with lysosomal membrane
(Sahu et al., 2011; Uytterhoeven et al., 2015; Mukherjee
et al., 2016; Oku et al., 2017). This process is responsible for
maintaining the turnover of cellular nutrients via both a selective
and hsc70-mediated mechanism or bulk degradation of proteins
and organelles, such as mitochondria, peroxisomes and portions
of nucleus (Olsvik et al., 2019). While microautophagy requires
autophagic proteins participation, endosomal microautophagy is
strongly associated with endosomal trafficking, which requires
ESCRT complex that together with hsc70 mediates a more
selective degradation (Sahu et al., 2011; Uytterhoeven et al.,
2015; Mukherjee et al., 2016; Oku et al., 2017). Thus hsc70
exerts its function in both CMA and endosomal microautophagy,
depending on the interactor protein.
Recently, different studies described another autophagic
pathway, named “Precision Autophagy” (Kimura et al., 2015).
Precision Autophagy is a receptor-regulator-mediated type of
autophagy which requires factors that are part of the tripartite
motif (TRIM) protein family that can act as both receptors and
regulators of autophagy at the same time. Such proteins are
capable of identifying their targets, even without the need of a
tag, such as ubiquitin and galectins (Stolz et al., 2014). Those
proteins exert their function by first recognizing exogenous
and endogenous cargos through their C-terminal domain. After
substrates recognition, TRIMs, acting as a receptor, stimulate
autophagy by facilitating the assembly of autophagic machinery,
primarily acting on ULK1, Beclin-1, ATG16L1 in their activated
status. However, TRIMs-modulated autophagy can both enhance
or reduce autophagic flux. In fact, TRIM28 can either positively
modulate Beclin-1 activity through VPS34 activation (Yang et al.,
2013) or mediate AMPK degradation acting as an E3 ligase
(Pineda et al., 2015).
AUTOPHAGY AND HEALTHY AGING
Aging is a time-mediated physiological process which carries
a decline in several molecular and cellular mechanisms
contributing to cellular homeostasis. Defective proteostasis has
been largely reported in a plethora of in vitro and in vivo aging
models (Cuervo et al., 2005; Boland and Nixon, 2006; Balch
et al., 2008; Ben-Zvi et al., 2009; Bingol, 2018; Boland et al.,
2018). Bergamini et al. (2004) provided the first evidence that
the efficiency of autophagy and, consequently, of detoxification
mechanisms, worsen along with aging in liver tissue (Donati
et al., 2001; Del Roso et al., 2003). Therefore, assessing the
causes of autophagic dysfunction during senescence became
fundamental in order to delay age-related phenotype in both
physiological and pathological conditions. Autophagic decline
has been considered as one of the major contributors to
the age-dependent accumulation of dysfunctional organelles,
cytoplasmatic content and misfolded/aberrant proteins that
might combine to form potentially cytotoxic aggregates.
Furthermore, failure in replacing old organelles, especially
lysosomes, mitochondria and endoplasmic reticulum (ER), has
important consequences on their morphology and functions,
other than cellular homeostasis. In fact, one of the morphological
features associated with senescence is the presence of enlarged
lysosomes containing deposited lipofuscin, i.e., a pigment
formed by a highly oxidized cross-linked protein aggregates,
carbohydrates and lipids, remarkably resistant to proteolytic
activity of lysosomal enzymes. Moreover, lipofuscin represents
an important source of ROS via the Fenton reaction. Another
common feature associated with ALP deficiency is the increase
number of autophagic vesicles, detected by electron microscopic
(EM) and immunofluorescence in different tissues (brain, heart,
muscle and kidney). This scenario is exacerbated in postmitotic
cells, such as neurons, where lipofuscin accumulation is even
greater due to their reduced ability to dilute it through mitotic
cycles (Rezzani et al., 2012).
Dysfunctional and damaged mitochondria are responsible for
increased oxidative stress and free radical production (Rezzani
et al., 2012). In 1956, Harman proposed “the free radical
theory” according to which ROS damage cellular functions
ensuing in the characteristic aging phenotype. In senescent
cells, increased ROS production as well as reduced ROS cellular
detoxification can damage mtDNA, causing an accumulation
of mitochondrial mutations and hypoxia in senescent tissues,
such as brain (Roberts et al., 1997), heart (Pepe, 2000), and
kidney (Nangaku et al., 2008). Moreover, this age-related increase
in oxidative stress may lead to enhanced protein oxidation,
causing unfolding, exposure of hydrophobic residues and, finally,
aggregation (Miquel, 1998; Hohn et al., 2017). In particular,
ALP plays a more relevant role than UPS in promoting ROS
detoxification. Indeed, chronic oxidative stress causes ATGs
overexpression and mTORC1 inhibition, leading to an increased
autophagic, but not proteasomal, activity (Chakraborty et al.,
2019). Autophagy stimulation, e.g., by rapamycin treatment, can
reverse increased ROS production, promoting neuronal survival
(Ramirez-Moreno et al., 2019). Trehalose is another effective
autophagy enhancer that can protect against oxidative stress in an
mTORC1-independent manner. Trehalose is a naturally available
disaccharide that facilitates the autophagic flux and exerts anti-
oxidant effects by promoting the nuclear translocation of Nrf2,
and the transcription of Nrf2 target genes (Mizunoe et al., 2018).
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Aging has also been associated with activation of the immune
response by several DAMPs, which are molecules capable of
triggering the production of proinflammatory cytokines and
chemokines, growth factors and components of extracellular
matrix. The circular mtDNA and some mitochondrial proteins,
like N-formyl peptides and cardiolipin, coming from senescent
mitochondria, act as DAMPs through activating Toll-like
receptor 9 signaling and formyl peptide receptor-1, respectively,
causing an enhanced cytokine production from cultured
monocytes (Pinti et al., 2014; Jang et al., 2018).
Impaired mitophagy is another common feature of aging
(Sun et al., 2016). Mitophagy is a selective form of autophagy,
since it regulates the removal of old and excessive mitochondria.
Mitophagy starts with the recognition and targeting of damaged
mitochondria, mediated by PINK1. PINK1 accumulates at the
outer membrane of damaged mitochondria, where it recruits
Parkin, an E3 ubiquitin ligase, which participates to mitochondria
sequestration by autophagosomes (Jin and Youle, 2012). Age-
related mitophagy decline is characterized by dysfunctional,
fragmented and swollen mitochondria, which is accompanied by
lower PINK1 expression in murine lung tissue (Sosulski et al.,
2015) and aged cells (Terman et al., 2010).
Reduced clearance of damaged/dysfunctional organelles is not
the only consequence of defective autophagy, since accumulation
of long-lived, misfolded, oxidized proteins also occurs during
aging. In fact, ALP, and to a lesser degree UPS are impaired
in senescent tissues. LAMP1 and LAMP2A levels markedly
decrease over the years resulting in a defective CMA activity.
In aged cells, the decrease of LAMP2A levels is initially
compensated by an increase of lysosome number (Cuervo
and Dice, 2000; Ott et al., 2016). In senescence, however,
the compensatory increase of the number of lysosomes and
chaperones fails to further sustain CMA activity rate due to
the increasingly small amount of LAMP2A. As a proposed
mechanism, aging can affect either LAMP2A recycling from the
lysosomal lumen or its stability at the lysosomal membrane.
Indeed, lysosomal membrane accumulates cholesterol during
aging, which results in an enhanced fluidity, and ultimately
prevents LAMP2A multimerization (Rodriguez-Navarro et al.,
2012). The increased quantity of cholesterol and ceramides
can also create enlarged degradation membrane domains where
LAMP2A accumulates and is degraded, which further reduces its
abundance (Rodriguez-Navarro et al., 2012).
Likewise, autophagy decline is associated with a decrease
in either autophagosomes formation or clearance (Bergamini
and Signorini, 1991). It has been reported that the decreased
autophagosomes formation might be due to reduced ATGs
content, whereas the decrease of autophagosome clearance may
be related to impaired fusion with the lysosomes and lysosomal
activity (Kenessey et al., 1989; Sitte et al., 2000a,b).
Another contributor to impaired autophagy during aging is
upregulation of mTOR pathway. In fact, mTORC1 inhibition
has been widely investigated as a potential mechanism to slow
down aging and promote life span extension. The first evidence
of the role of autophagy in life-span expansion came from
studies in C. elegans, where mutants of daf-2, a gene encoding
insulin growth factor (IGF-1) receptor, showed reduced longevity
due to the silencing of the autophagy gene bec-1, the ortholog
of beclin-1. This suggested for the first time that enhancing
autophagy would increase life-span (Melendez et al., 2003).
Indeed, knocking down key autophagy proteins dramatically
reduced the life-span of daf-2 mutants (Melendez et al., 2003;
Hars et al., 2007). The most effective methods to inhibit mTORC1
signaling in order to selectively activate autophagic machinery
are caloric restriction (CR) and pharmacological blockage
through administration of rapamycin or similar compounds
(“rapalogs”) (Kapahi et al., 2010; Galluzzi et al., 2017). CR, a
limiting food intake strategy without malnutrition, has been
studied as a powerful anti-aging physiological intervention. CR-
mediated autophagy enhancement requires activation of two
energy sensors, like AMPK and Sirtuin 1, and inhibition of
insulin/insulin-like growth factor (IGF) pathway, which, in
turn, leads to downstream mTORC1 blockage. Abolition of
high metabolic rate characterizing senescent cells is one of
the accepted mechanisms by which reduced insulin/insulin-like
growth factor or mTORC1 signaling promote longevity (Toth
et al., 2008). Furthermore, mTORC1 plays a central role in the
release of pro-inflammatory cytokines by old cells, a process
named senescence-associated secretory phenotype (SASP) which
is reversed by rapamycin treatment (Laberge et al., 2015).
Moreover, in yeast, worms or flies CR is ineffective when
mTORC1 pathway is already downregulated, demonstrating that
a common signaling cascade underlies both strategies of life-span
expansion (Grandison et al., 2009). Pharmacological blockade
as well as genetic inhibition of mTORC1 increase life-span in
several animal species, such as C. elegans (Vellai et al., 2003),
D. melanogaster (Kapahi et al., 2004), S. cereviasiae (Kaeberlein
et al., 2005), and mice (Harrison et al., 2009). On the contrary,
ATG genes knockout or knockdown reverses life-span extension
induced by rapamycin, suggesting that rapamycin selectively
affects and enhances autophagosome formation. However, it is
possible that other mechanisms come into play to extend the
life-span, such as a reduced oxidative stress, as shown in rats
(Moyse et al., 2019).
AUTOPHAGY AND
NEURODEGENERATION
Autophagy is involved in maintaining proteostasis and general
neuronal homeostasis, synaptic remodeling and activity, axo-
dendritic plasticity and mitochondrial clearance in CNS. Both
clinical studies and preclinical models described neuronal
atrophy, reduced cargo amount, impaired autophagy and
mitophagy in age-related diseases (Boland and Nixon, 2006;
Menzies et al., 2017; Boland et al., 2018). To further investigate
the specific role of autophagy in neuronal cell-types, several
Atg5 and Atg7 KO models have been developed (Galluzzi et al.,
2017; Boland et al., 2018). Those studies provided evidence that
autophagy is essential for axonal homeostasis and that each
neuronal cell type responds differently to autophagy decline
due to a diverse susceptibility to cytotoxic proteins aggregation
(Tsvetkov et al., 2013). Atg5 and Atg7 KO mice showed early
onset neurodegeneration, while beclin-1 knockdown increased
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susceptibility of hippocampal neurons to energy deprivation
(Fekadu and Rami, 2016). Furthermore, selective and conditional
genetic deletion, via Nestin-Cre technology, of Atg5 and Atg7
causes defective autophagy and consequent accumulation of
intracellular aggregation-prone proteins in neurons and glia
(Hara et al., 2006; Komatsu et al., 2006a, 2007b). Although
the aged brain is accompanied by a deficiency in both general
and selective types of autophagy (see above), an increased
compensatory mitophagy in the later phase of neurodegenerative
diseases has been observed. In fact, beyond ATP production,
mitochondria are also involved in protein clearance, as proven
by the intake of aggregation-prone proteins, such as amyloid-β,
superoxide dismutase 1 (SOD1) variants and α-syn. Nevertheless,
this compensatory process leads to a higher chance of developing
mitochondria damage due to increase exposure to cytotoxic
proteins, like α-syn. Therefore, enhancing PINK1-Parkin-driven
mitophagy has been viewed as a strategy to improve both
mitochondria quality control and protein degradation (Hertz
et al., 2013; Georgakopoulos et al., 2017).
Neurodegenerative disorders of aging, such as AD, PD,
and HD, have as a common feature the formation of
cytotoxic aggregates. Those aggregates are made of proteins
that can be oxidized, wrongly processed, misfolded or cross-
linked by cellular post-translational machinery. These proteins
are considered “toxic” because they lose their physiological
conformation and functions, alter cellular trafficking, and block
CMA or UPS, promoting their spreading throughout the
CNS in a prion-like manner (Brundin et al., 2010; Brundin
and Melki, 2017). Moreover, neurons are postmitotic cells,
thus are not capable of diluting protein aggregates through
mitotic cycles, making cells even more susceptible to their
potential toxicity properties. In fact, neurons activate different
compensatory mechanisms to reduce protein accumulation,
for instance sequestering them in hydrophobic agglomerates
or combining them with microtubules to form aggresomes
(Ciechanover and Kwon, 2017). Even though this strategy can
be neuroprotective in the early stages of age-related diseases,
it fails to handle the increased cytotoxic burden in the later
stages. As reported above, autophagy declines physiologically
with senescence. In the context of neurodegenerative diseases,
this age-dependent decline appears to be exacerbated because
it is accompanied by the impairment of ALP machinery due
to the accumulation of neurotoxic proteins. Furthermore, in
most cases, neurodegenerative diseases are associated with the
inheritance of mutations in genes controlling the autophagic
process, suggesting that aberrant autophagy might contribute to
neurodegeneration (Ravikumar et al., 2002; Berger et al., 2006;
Ravikumar et al., 2006).
Autophagy and Parkinson’s Disease
The neuropathological hallmarks of PD are the loss of dopamine
(DA) neurons in the SNpc and the accumulation of intracellular
aggregates containing α-syn, named LBs. Changes in ALP
markers were reported in the human brain which are consistent
with an impairment of autophagic machinery. A significant
reduction of lysosomal and CMA markers, such as LAMP1,
LAMP2A, Hsc70 or Cathepsin D, associated with an increase
of autophagic markers LC3II and p62 levels, was reported
in the whole-brain (Mamais et al., 2018) or SNpc (Chu
et al., 2009; Dehay et al., 2010) of idiopathic PD patients
(Xilouri and Stefanis, 2015). Moreover, LC3II has been shown to
colocalize with α-syn in LBs (Alvarez-Erviti et al., 2010; Dehay
et al., 2010). The patterns of ALP markers were compared in
the brains of idiopathic vs. G2019S LRRK2 PD patients (Mamais
et al., 2018). Interestingly, G2019S PD patients did not show the
increase of LC3II, p62 and ULK-1 levels observed in idiopathic
PD patients, but instead a significant reduction of LAMP1 levels.
This was interpreted as being due to a different pathobiology
associated with idiopathic and G2019S LRRK2 PD (Mamais
et al., 2018). Consistent with this view, G2019S LRRK2 cases
had lower insoluble α-syn levels compared to idiopathic PD
patients, suggesting differences in the biochemical properties of
aggregated α-syn (Mamais et al., 2013). In another study, an
increase of LAMP2A but not LAMP1 levels was reported in
the cholinergic cells of the motor nucleus of the vagal nerve in
G2019S LRRK2 patients compared to non-neurological controls,
which was explained as being due to either a compensation for
impaired CMA or a chronic reduction in LAMP2A turnover
(Orenstein et al., 2013). ALP changes were also investigated in
the brains of patients suffering from dementia with LB (DLB),
another type of synucleinopathy, in comparison with brains of
AD patients (Crews et al., 2010; Higashi et al., 2011). In the first
study, an increase of mTOR along with a reduction of ATG7 (but
not beclin-1, ATG5 or ATG12) was detected in DLB vs. AD brains
(Crews et al., 2010) whereas in the latter study, an increase of
LC3II was observed in DLB but not AD patients, a reduction of
LAMP2 levels being common (Higashi et al., 2011). These two
studies suggest different roles of autophagy in these diseases.
Studies on mitophagy in PD were the first ones to elucidate
the crucial role of autophagy in age-related degeneration in CNS.
In fact, blocking mitochondrial complex I by administration
of low doses of MPP+ is one of the most common strategies
to study PD pathogenesis (Zhu et al., 2012). Early onset
autosomal recessive forms of PD, also have been related to
mutations in genes that encode PINK1 (Valente et al., 2004)
and the E3 ubiquitin ligase Parkin (Kitada et al., 1998),
both involved in recognition, targeting and degradation of
damaged mitochondria. Although no behavioral changes have
been observed in Parkin−/− mice (Goldberg et al., 2003; Itier
et al., 2003; Perez and Palmiter, 2005), disrupted mitochondrial
function, response to DA and synaptic plasticity occur in
the striatum (Palacino et al., 2004; Kitada et al., 2009). Even
Pink1 deletion results in impaired mitochondrial function and
increased susceptibility to oxidative stress in mice (Gautier
et al., 2008). Enhancing PINK1 activity has been reported to
rescue from apoptotic signals, representing a potential strategy
for idiopathic PD (Petit et al., 2005; Pridgeon et al., 2007;
Klinkenberg et al., 2010). Accordingly, administration of kinetin,
a precursor of an ATP analog, increases PINK1 function as
proven by a more abundant phosphorylated form of Bcl-xL, a
protein that mediates mitochondrial-induced apoptosis (Adams
and Cory, 1998; Gross et al., 1999). Moreover, kinetin can
promote PINK1-dependent recruitment of Parkin on the outer
depolarized mitochondrial membrane allowing mitophagy to
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start (Hertz et al., 2013). Therefore, restoring mitophagy rate
might be a new neuroprotective strategy to reduce DA neuron
degeneration typical of PD (Park et al., 2017).
There is evidence for a causative relationship between CMA
dysfunction and intracellular accumulation of α-syn, a common
feature of PD. Indeed, α-syn is a qualified substrate for CMA as
it bears a KFERQ-like motif. Downregulating key components
of CMA pathway, such as LAMP2A in rat midbrain (Xilouri
et al., 2016) and Hsc70 in neuronal cell models (Sala et al.,
2016), leads to increase of α-syn intracellular content, neural
loss and behavioral deficits in rats. Furthermore, either stress-
mediated or PD-linked A30P and A53T mutations in the α-syn
gene (SNCA) determine the production of aberrant α-syn which
displays a fivefold higher affinity for LAMP2A compared to
the WT protein, preventing LAMP2A translocation across the
lysosomal membrane and degradation of CMA targets (Cuervo
et al., 2004; Martinez-Vicente et al., 2008). Mutations in GBA,
which encodes the lysosomal enzyme GCase, are major risk
genetic factors for PD, since they lead to a protein loss-of-
function and lysosomal dysfunction. Mutations in GBA are
major genetic factors for PD, encoding the lysosomal enzyme
GCase, which leads to a protein loss-of-function and lysosomal
dysfunction. The GBA1 homozygous mutations, instead, cause
a lysosomal storage disorder, named Gaucher Disease which
is characterized by excessive accumulation of glucosylceramide,
a GCase substrate, into the lysosomal lumen, with subsequent
autophagy impairment. The relevance of this pathway is further
strengthened by the finding that even PD patients without
GBA1 mutations showed a reduced GCase activity in the same
cerebral areas displaying α-syn deposition (Mazzulli et al.,
2011; Murphy et al., 2014). Besides, it has been reported
that chronic pharmacological blockade of GCase in A53T
α-syn transgenic mice further promoted exosome-associated
α-syn accumulation and secretion. This supported the view
that GCase directly regulates α-syn extracellular homeostasis
and might be studied as a new therapeutic target in PD
(Papadopoulos et al., 2018).
LRRK2 AND AUTOPHAGY
LRRK2 is a large multidomain protein with central GTPase Ras-
of-Complex (ROC) and kinase domains, surrounded by protein-
protein interaction domains (Mata et al., 2006; Cookson, 2010;
Mills et al., 2014). LRRK2 mutations are the most common
genetic cause of familial PD (Zimprich et al., 2004; Paisan-Ruiz
et al., 2005) and GWAS studies revealed LRRK2 represents a
risk factor for idiopathic PD (Nalls et al., 2014). At least six
pathogenic mutations of LRRK2 have been identified: two in the
kinase domain (G2019S and I2020T), three (R1441C/G/H) in the
GTPase/ROC domain, and one (Y1669C) in the CoR domain
(Reed et al., 2019). The G2019S mutation is most frequently
associated with PD, followed by R1441C/G/H (Gasser, 2009;
Okubadejo et al., 2018). LRRK2-associated PD is clinically and
neuropathologically indistinguishable from idiopathic PD, most
cases, particularly G2019S cases, presenting with nigrostriatal
dopaminergic degeneration and LBs (Marras et al., 2011;
Kalia et al., 2015). The penetrance of LRRK2-mediated PD is
age-dependent but incomplete. LRRK2 mutations facilitate PD
through several possible mechanisms, since LRRK2 is involved
in a multitude of cellular functions and pathways, among
which vesicle trafficking, cytoskeletal dynamics, neurotransmitter
release, synaptic plasticity, Golgi and mitochondrial function,
and immune response. In addition, several studies have pointed
out the role of LRRK2 in autophagy (Roosen and Cookson,
2016; Manzoni and Lewis, 2017), which will be covered in
the next chapters.
In vitro Studies
The first indirect evidence of LRRK2 modulation of proteostasis
came from the 2006 study of MacLeod et al. (2006) showing
that primary cortical neurons overexpressing G2019S or I2020T
LRRK2 had tau-positive aggregates, MVB accumulation and
swollen lysosomes (Table 1). That LRRK2 modulates autophagy
was shown for the first time by Plowey et al. (2008) in SH-
SY5Y neuroblastoma cells overexpressing WT LRRK2, G2019S
LRRK2 (a kinase-enhancing mutation) (West et al., 2005; Greggio
et al., 2006), or K1906M LRRK2, a kinase dead (KD) mutation
(Table 1). Cells overexpressing G2019S LRRK2 displayed neurite
shortening, together with an increase in the number and size of
LC3-reactive autophagic vacuoles (AV), both at the neuritic and
the somatic levels. The autophagic inducer, rapamycin, further
enhanced these effects whereas blocking autophagy through
LC3 or Atg7 knock-down (with RNA-interference) caused their
reversal, suggesting that G2019S overexpression is associated
with enhanced autophagy and neurite shortening. It is worth
noting that in this model, neither WT LRRK2 nor K1906M
LRRK2 overexpression altered the autophagic flux, suggesting
that not the loss but the increase of kinase activity might
be instrumental to LRRK2 neurotoxic effect. Other studies
confirmed that G2019S or R1441C LRRK2 mutants are associated
with an increased autophagy (Gomez-Suaga et al., 2012b; Bravo-
San Pedro et al., 2013; Orenstein et al., 2013; Su and Qi,
2013; Yakhine-Diop et al., 2014; Su et al., 2015). Nonetheless,
others in vitro studies in different cell lines showed that LRRK2
G2019S and/or R1441C overexpression leads to inhibition of
autophagy (Alegre-Abarrategui et al., 2009; Sanchez-Danes et al.,
2012; Manzoni et al., 2013a, 2016; Wallings et al., 2019).
A possible difference between mutations in the Roc-COR and
kinase domains in terms of response to starvation-induced
autophagy was also reported (Manzoni et al., 2013b). G2019S
LRRK2 overexpression was also found to inhibit specific forms
of autophagy such as CMA (Orenstein et al., 2013) or mitophagy
(Wauters et al., 2019); in these studies, autophagy was found
to be increased (possibly to compensate for CMA blockade)
(Orenstein et al., 2013) or to be unchanged (Wauters et al.,
2019). The role of the kinase activity of LRRK2 was investigated
using LRRK2 kinase inhibitors. LRRK2-IN1, GSK2578215A and
CZC25146 were reported to increase (Manzoni et al., 2013a,
2016) or to inhibit (Saez-Atienzar et al., 2014; Schapansky
et al., 2014) the autophagic flux in vitro. Unfortunately, first
generation inhibitors were employed in these studies, which
are characterized by low kinase specificity and off-target effects
(West, 2017). Interestingly, however, more selective LRRK2
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TABLE 1 | Synopsis of the in vitro studies investigating the impact of genetic and pharmacological manipulation of LRRK2 on autophagy and its markers.
Cell type LRRK2 manipulation Autophagic marker Phenotype





Plowey et al., 2008 SH-SY5Y G2019S OE ↑ LC3 puncta,
↑ AV number and size
↑ autophagy
Neurite shortening, potentiated
by rapamycin and reversed by
LC3 or Atg7 kd but not 3-MA.
Blocked by MEK-inhibitor
WT, K1906M OE (KD) ↔
Alegre-Abarrategui et al., 2009 HEK293T, VERO R1441C, G2019S OE ↑ LC3 puncta,
↑ MVB and AV
↓ autophagy
Colocalization of LRRK2 with
p62 and LC3 in MVB and AV,
skein-like inclusions in R1441C
transfected cells




cell death in starvation
conditions
Gomez-Suaga et al., 2012b HEK293T, PC12 WT, G2019S OE ↑ LC3 puncta, ↑ LC3II levels
↑ mature lys
↑ autophagic structures




Increase cell-death triggered by
an UPS inhibitor (rescued by
rapamycin)
K1906M OE (KD) ↔
Sanchez-Danes et al., 2012 Human-derived iPSC G2019S ↑ LC3 puncta
↑ lipid droplets,
↑ p62, ↓ LC3 flux, ↓ AV
↓ autophagic clearance
Shorter/fewer neurites




WT OE ↑ LAMP2A Impaired CMA with
compensatory ↑ autophagy
G2019S OE ↑ LAMP2A
↔ LC3
LRRK2 kd ↔
Bravo-San Pedro et al., 2013 Human fibroblasts G2019S ↑ autophagic flux,
↑ AP, ↓ p62
↑ LAMP2A, LC3, beclin-1
Inhibited by MAPK1/3 inhibitor









Manzoni et al., 2013b Human fibroblasts G2019S, R1441G, Y1699C ↓ LC3II/LC3I after starvation,
↓ p62-positive in LRRK2
Y1699C and R1441G cells,
↔ p62, LAMP1 levels
mTOR-independent












and cell-death. Exacerbated by
autophagy inhibitors








↓ clearance of Q74 protein
aggregates in microglial cells
Yakhine-Diop et al., 2014 Human
fibroblasts




↑ MPP+-induced cell death,
MPP+-dependent mTOR
dephosphorylation
Su et al., 2015 Human
fibroblasts
G2019S ↑ autophagic flux Mitochondrial depolarization
and mass loss
(Continued)
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TABLE 1 | Continued
Cell type LRRK2 manipulation Autophagic marker Phenotype












Primary astrocytes LRRK2 KO ↑ LC3II







↔ Rescues lys changes and
reduces α-syn aggregates




↑ LC3II, ↓ p62 BFA-insensitive
LRRK2 KO As above
Wallings et al., 2019 Primary rat cortical neurons R1441C ↑ LC3II,↔ p62, LAMP1
↓ autophagic flux,
↓ AP-lys fusion
↓ lys protein degradation
↑ lys pH
Unresponsive to LRRK2 kinase
inhibition (MLi-2, PF06447475)
WT, G2019S ↓ autophagic flux Reversed by LRRK2 kinase
inhibition
Non transgenic ↓ autophagic flux after LRRK2
kinase inhibitors
LRRK2 KO ↑ LC3II,↔ p62, LAMP1
↑ lys protein degradation
Ho et al., 2019 MEF, primary neurons R1441G ↓ lys activity









Bonello et al., 2019 COS7
Human fibroblasts
G2019S, R1441C N/A Impairs Pink1/parkin-mediated
mitophagy




↑ increase, ↓ decrease, ↔ no change; A, autophagosome; AV, autophagic vacuoles; BFA, bafilomycin A1; kd, knock-down; KD, kinase dead; KO, knock-out; Lys,
lysosomes/lysosomal; MEF, mouse embryonic fibroblasts; MVB, multi-vesicular bodies; OE, overexpression; vmDA, ventral midbrain dopamine.
inhibitors MLi-2 and PF-06447475 increased the autophagy flux
in primary cortical neurons obtained from BAC G2019S (but
not R1441C) mice causing the opposite effect in non-transgenic
cultures (Wallings et al., 2019). The issue of whether LRRK2 acts
as negative or positive modulator of autophagy is also still unclear
(Table 1). Neurons or macrophages obtained from LRRK2 KO
mice show an increase of LC3II levels and autophagic flux,
suggesting that endogenous LRRK2 inhibits autophagy (Manzoni
et al., 2016; Hartlova et al., 2018; Wallings et al., 2019). However,
most studies reported that WT LRRK2 overexpression increased
autophagy (Gomez-Suaga et al., 2012b; Orenstein et al., 2013;
Su and Qi, 2013; Roosen and Cookson, 2016), with one study
(Plowey et al., 2008) reporting no effect and, another (Wallings
et al., 2019), inhibition. Acute knock-down of LRRK2 was
shown to be ineffective (Orenstein et al., 2013; Manzoni et al.,
2016), to increase (Alegre-Abarrategui et al., 2009) or to inhibit
(Schapansky et al., 2014) autophagy. Therefore, not only the
regulation of autophagy operated by LRRK2 is mechanistically
complex, but also experimental outcomes seem to be affected by
a number of variables including the cell model, expression levels
of LRRK2, LRRK2 kinase inhibitor used, autophagic markers
investigated and protocols adopted (Klionsky et al., 2016). In
this respect, it should be noted that although autophagy was
monitored through quantification of LC3II levels, not all studies
investigated the autophagic flux, i.e., fold-changes following
application of autophagy inhibitors, which would allow to
conclude whether the increase of LC3II levels is due to an




The first published evidence that LRRK2 affects autophagy
in vivo was produced in yeasts where administration of fragments
of human LRRK2 carrying mutations that impair GTPase
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TABLE 2 | Changes in autosomal-lysosomal pathways in LRRK2 KO mice and rats in vivo.
Strain age (mos) Brain Kidney α -syn levels Note









Herzig et al., 2011 LRRK2 KO mice
(14 m)
N/A ↑ Akt, TSC2, mTOR,
4E-BP1 and pT37/46
4EBP1, ↑ p62
↔ pT308 Akt, S6,
LC3I/II
↔ Mild ↑ lamellar bodies
in lung type II
pneumocytes
Tong et al., 2012 LRRK2 KO mice
(7 m)











↑ α-syn soluble and
insoluble fraction
Hinkle et al., 2012 LRRK2 KO mice
(12 m,18 m)
N/A ↑ p62 ↔
Baptista et al., 2013 LRRK2 KO rats
(1–12 m)
N/A ↑ LAMP1, LAMP2A N/A Age-dependent
Fuji et al., 2015 LRRK2 KO mice
(2–3 m)
N/A ↑ lysosomes N/A ↑ lamellar bodies in
lung type II
pneumocytes
Giaime et al., 2017 LRRK KO∗ mice
(15 m)
↑ α-syn or ub ↑ p62,
↓ LC3I, ↑ LC3II
N/A ↑ α-syn and HMW
α-syn in striatum and
SNpc but not CCx
Age-dependent
∗Mice lacking both LRRK1 and LRRK2, i.e., double KO mice. ↑ increase, ↓ decrease,↔ no change; AP, autophagosome; Cath, cathepsin; CCx, cerebral cortex; HMW,
high molecular weight; SNpc, substantia nigra pars compacta; ub, ubiquitinated proteins.
activity caused neuronal death, vesicle trafficking defects and
AV accumulation (Xiong et al., 2010) (Table 2). In Drosophila
melanogaster (Imai et al., 2008) pointed out that LRRK2
modulates protein synthesis through phosphorylation of eIF4E
binding protein (4E-BP), which lies along the mTOR pathway,
suggesting that LRRK2 modulates ALP. Overexpression of WT
or I2020T LRRK2 hyperphosphorylated 4E-BP, which resulted
in reduced 4E-BP binding to eIF4E, and deregulation of protein
translation. Interestingly, however, no changes in levels or
phosphorylation of mTOR were found, questioning the role
of autophagy in these events (Imai et al., 2008). Later study
in Drosophila melanogaster more convincingly proved the role
of autophagy in LRRK2 toxicity, showing that activation of
autophagy via pharmacological or genetic stimulation of AMPK
protected against mitochondrial toxicity and DA cell loss induced
by expression of human G2019S LRRK2 (Ng et al., 2012).
ALP defects were also observed in follicle cells of Drosophila
melanogaster, where the LRRK2 homolog Lrrk colocalizes with,
and binds to Rab7 and Lamp1 in late endosomes and lysosomes,
and to a much lesser extent to Rab5 in early endosomes (Dodson
et al., 2012, 2014). Lrrk null flies showed enlarged Rab7-positive
structures containing undigested cytosolic material, increased
autophagosomes and enlarged early endosomes containing
monoubiquitinated proteins, consistent with the view that loss of
Lrrk function blocks the late endosomal to lysosomal maturation,
impairs the degradative properties of lysosomes and the substrate
delivery to lysosomes. Interestingly, this phenotype was reversed
by overexpression of WT Lrrk or G1914S Lrrk (a mutant with
enhanced kinase activity equivalent to G2019S LRRK2) (Dodson
et al., 2014). Studies in C. elegans also demonstrated that LRRK2
regulates autophagy. Saha et al. (2015) using a fluorescence
gene reporter fused with lgg-1, the LC3 homolog, revealed that
aging impairs the autophagic flux: hG2019S or hR1441G LRRK2
worsened this effect whereas WT LRRK2 and a LRRK2 KD
mutant improved it. Nonetheless, when co-expressed with α-syn,
both G2019S LRRK2 and, to a lesser extent, WT LRRK2, impaired
autophagy in an age-dependent way, which was associated with
a greater loss of DA neurons in older nematodes (Saha et al.,
2015). Interestingly, a minimal effect of G2019S LRRK2 on
the expression of the LAMP1 homolog, lmp-1, was detected,
suggesting that, at variance with Drosophila, LRRK2 minimally
altered lysosomal function (Saha et al., 2015).
Rodents
Original study in LRRK2 KO mice failed to find brain pathology
(nigrostriatal degeneration and α-syn or ubiquitinated protein
accumulation) and changes in brain autophagy markers in
2-year-old LRRK2 KO mice (Tong et al., 2010) (Table 2).
Nonetheless, this study unraveled that loss of LRRK2 caused
striking age-dependent pathology selectively in the kidney, which
expresses the highest levels of LRRK2 in the mouse (sixfold
greater than in the brain). An increase of both soluble and
insoluble forms of α-syn, along with the levels of pSer129-
α-syn, were found at 20 months but not at 10 weeks of
age. Since α-syn is degraded by ALP and UPS, this pointed
to an impairment of α-syn clearance in aged kidneys. An
impairment of UPS and ALP due to the deletion of LRRK2 was
further suggested by the accumulation of ubiquitinated high-
molecular weight proteins and lipofuscin granules, and by the
analysis of the autophagic flux, which revealed mild elevation
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of LC3I, dramatic reduction of LC3II levels, and compensatory
accumulation of p62.
The same groups of authors later observed (Tong et al.,
2012) that changes in ALP function were actually biphasic. At
7 months, a reduction of LC3I/LC3II ratio and p62 levels was
associated with a reduction of insoluble α-syn aggregates (soluble
α-syn levels were undetectable), indicating an increase of ALP
activity, whereas at 20 months an increase of LC3I/LC3II ratio
and p62 levels was associated with elevation of both soluble and
insoluble α-syn levels, indicating normalization of autophagy.
Analysis of lysosomal proteins and proteases at key ages did not
reveal qualitative age-dependent changes since levels of LAMP1
and LAMP2 as well as cathepsin B were found to be elevated
already from the first month of age (significant elevation of
cathepsin D was observed at both 7 and 20 months). However,
EM analysis revealed kidney-specific age-related accumulation
of autolysosomes and lipofuscin granules confirming that loss
of LRRK2 is associated with lysosomes alterations. Kidney
pathology in LRRK2 KO mice was substantially confirmed by
Hinkle et al. (2012) and Fuji et al. (2015). These authors
analyzed kidneys at 3, 12, and 18 months. Pigmentation and
lipofuscin staining, already evident at 3 months, worsened with
aging. p62 levels progressively increased with age, at variance
with WT controls where they appeared at 12 months. Different
from previous studies, however, no changes in α-syn staining
was observed in these mice. Also at variance with previous
data, elevated LC3II were detected in 18-month-old LRRK2
KO mice, with no difference observed at younger ages (Hinkle
et al., 2012). Likewise, LRRK2 KO rats (Baptista et al., 2013)
showed striking age-dependent kidney pathology, with lipofuscin
accumulation and irregular hyaline droplets accumulation in
kidney tubular epithelium, starting at 4 months. In the same
cells, progressive increase of immunohistochemical staining for
LAMP1 and LAMP2 was noted, which was overall interpreted as
an impairment of lysosomal function.
Novartis group analyzed in great detail autophagy in 14-
month-old LRRK2 KO mice in comparison with 5-month-old
G2019S KI mice, which show enhanced kinase activity in vivo
(Yue et al., 2015; Longo et al., 2017; Mercatelli et al., 2019),
and 6-month-old KD mice, which instead show no kinase
activity in vivo (Herzig et al., 2011; Mercatelli et al., 2019).
Microvacuolization in tubular epithelial cells of LRRK2 KO mice
appeared already at 1.5 months, and progressively worsened
over time, with lipofuscin-like pigments appearing at 8 months.
Similar changes were observed for the first time also in type II
pneumocytes of lungs, other organs (brain, spleen, liver, heart)
being spared, indicating a crucial role for LRRK2 in kidney
and lung homeostasis. A similar pathology was observed in the
kidneys of KD, but not G2019S KI, mice, consistent with the view
that loss of LRRK2 or its kinase activity causes derangement of
kidney homeostasis (Herzig et al., 2011). In line with this, LAMP1
or LAMP2 immunohistochemical staining was elevated in 6–9-
month-old LRRK2 KO or KD mice, respectively. EM analysis
revealed progressive increase in number and size of secondary
lysosomes in LRRK2 KO mice, again confirming alteration in
lysosome homeostasis. In keeping with Hinkle et al. (2012) and
in contrast with Tong et al. (2010, 2012), no changes in α-syn
levels were observed in the kidney of these mice. This study
confirmed the elevation of p62 levels in the LRRK2 KO kidney
(Tong et al., 2010), and compared for the first time a wider panel
of autophagic and lysosomal markers using Western analysis.
The resulting picture, however, was quite confusing, since the
Akt/mTOR pathway was perturbed in all genotypes, but with
different patterns. Akt levels were elevated in KD and LRRK2 KO
mice, but not G2019S KI mice. However, TSC2 and mTOR levels
were reduced in KD and elevated in LRRK2 KO and G2019S KI
mice. Perhaps consistent with an overactivation of the Akt/mTOR
pathway with consequent autophagy inhibition, levels of the
mTOR-regulated translation initiation factor 4E-BP1 and its
phosphorylated Thr37/46 forms were also elevated in LRRK2 KO
mice whereas no changes were observed in G2019S KI mice.
S6 kinase levels were unchanged in all genotypes. So were LC3I
and LC3II levels in LRRK2 KO and KD mice (not investigated
in G2019S KI mice). Kidney and lung pathology were also
confirmed in 10–12 weeks LRRK2 KO mice by a Genentech study
aimed at assessing the safety of two LRRK2 inhibitors (GNE-
7915 and GNE-0877) (Fuji et al., 2015). This study also revealed
that administration of LRRK2 kinase inhibitors did not cause
vacuolization, i.e., lysosome dysregulation, in rodent tissues. At
variance with rodents, however, an increase of lamellar bodies in
type II pneumocytes of the lung of non-human primates, similar
to those observed in LRRK2 KO mice, was shown (Fuji et al.,
2015), which might be consistent with the view that inhibition of
LRRK2 kinase activity impairs autophagy. The different species
sensitivity was attributed to different residual LRRK2 levels
after LRRK2 inhibition (Fuji et al., 2015). It therefore appears
that removal of LRRK2 impairs ALP machinery in kidney and
pneumocytes. Nonetheless, subtle changes observed in G2019S
KI mice would not allow to rule out that also an increase
of LRRK2 kinase activity might perturb autophagy, possibly
indicating that ALP is physiologically regulated within a narrow
range of LRRK2 kinase activity.
What also clearly emerged from these studies is that genetic
deletion of LRRK2 does not impact autophagy in the brain.
A more recent study, however, revealed that the functional
homolog of LRRK2, i.e., LRRK1, might play a compensatory role
in LRRK2 KO mice (Giaime et al., 2017). Indeed, although any
changes of autophagic markers were found in mice constitutively
lacking either LRRK2 or LRRK1, double KO mice showed
age-dependent increase of p62 and LC3II levels, reduction of
LC3I levels, and AV accumulation, indicating an impairment
of autophagy (Giaime et al., 2017). Development of a selective
antibody might help elucidate the role of LRRK1 in autophagy
and, more in general, in cellular homeostasis.
Following the report of tau hyperphosphorylation in brain
lysates of 9–10-month-old LRRK2 BAC R1441C mice (Li et al.,
2009), the impact of LRRK2 mutants (i.e., LRRK2 G2019S
or R1441C/G) on brain autophagy was widely investigated
(Table 3). Autophagy abnormalities were detected in the
striatum of 17–18-month-old hG2019S transgenic mice
(enlarged AV and increased autophagosomes, associated
with aggregated and damaged mitochondria) (Ramonet
et al., 2011). Autophagy changes consistent with reduced
autophagic flux were also revealed in G2019S KI mice.
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TABLE 3 | Changes in autosomal-lysosomal pathways in LRRK2 mutant mice and rats in vivo.
Model Age (mos) Brain Kidney
α -syn Area NDG
Li et al., 2009 BAC R1441C
mice









































22 ↔ LC3, p62 No SNc No N/A





Yue et al., 2015 G2019S KI
mice







20 LAMP1, LC3I No CCx No N/A
Ho et al., 2018 G2019S TG
mice (PDGF
prom)
12-19 ↑ p62, LC3 ↑ Whole brain N/A N/A











22 ↑ LC3 puncta N/A SN No N/A
BAC R1441C
rats
22 ↑ LC3 puncta CCx SN
↑ increase, ↓ decrease, ↔ no change; AP, autophagosomes, c.f., cytosolic fraction; m.f., membrane fraction; NDG, nigrostriatal degeneration; prom,
promoter; TG, transgenic.
Specifically, 15-month-old G2019S KI mice showed an
increase of LC3II levels in a whole brain lysate (Yue et al.,
2015) whereas 20-month-old G2019S KI mice, showed a
reduction of LAMP1 in the cerebral cortex (Schapansky
et al., 2018). This was confirmed by experiments in primary
cortical neurons obtained from G2019S KI mice, where
autophagy impairment was reversed by LRRK2 inhibitors
(Schapansky et al., 2018). Moreover, 12–19-month-old G2019S
overexpressing mice showed accumulation of LC3 and p62
levels along with levels of GRB78/BiP, an ER stress marker
(Ho et al., 2018). In this study, it was shown that LRRK2
phosphorylates leucyl-tRNA synthetase, a regulator of protein
translation and mTOR interactor, and that G2019S LRRK2 is
associated with ER stress, accumulation of α-syn aggregates
and autophagic markers. It was therefore proposed that
inhibition of autophagy by G2019S LRRK2 would be secondary
to ER stress and misfolded protein engulfment (Ho et al.,
2018). Possibly in general agreement with previous studies,
22-month-old BAC G2019S and R1441C mice showed an
increase in LC3 puncta in SNpc DA neurons, as measured
by immunohistochemistry (Wallings et al., 2019). However,
considering the low expression levels of LRRK2 in mouse nigral
DA neurons (Biskup et al., 2006; Simon-Sanchez et al., 2006;
Taymans et al., 2006; Melrose et al., 2007; West et al., 2014), it
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is not clear whether these effects are truly LRRK2-dependent
and, if so, if they rely on LRRK2 kinase activity or scaffold
properties of LRRK2.
Autophagy abnormalities were observed also in R1441C/G
LRRK2 mutants, although more inconsistently. A pattern similar
to that observed in hG2019S KI mice was detected in 23–24
month-old hR1441C transgenic mice (Ramonet et al., 2011).
Conversely, conditional transgenic mice expressing the R1441C
mutation selectively in DA neurons, did not show accumulation
of α-syn, tau or ubiquitin or even changes of p62 and LC3
levels at the age of 12–22 months (Tsika et al., 2014). This
was confirmed also in R1441G KI mice, where no changes
in autophagic markers LC3 and Beclin-1 were observed at 3
and 18–22 months, when compared with age-matched WT
controls (Liu et al., 2014). Nonetheless, a more recent and
comprehensive study in these mice at different ages spanning
from 3 to 18 months, showed an age-dependent impairment of
CMA (Ho et al., 2019). In particular, Western analysis revealed
a significant increase in soluble α-syn and total amyloid-like
α-syn oligomers in 18-month-old but not younger R1441G KI
mice. Such increase of α-syn load was associated with lysosomal
redistribution, with clustering of lysosomes around the nucleus
of striatal neurons. Lysosomal impairment was confirmed by the
(mild) increase of LAMP2A and Hsc70 levels in the membrane
fraction of striatal lysates of 18-month-old mice, and by the
accumulation of a typical CMA substrate, such as GAPDH.
Further analysis in embryonic fibroblasts obtained from R1441G
mice proved that lysosomal clearance of α-syn was indeed
reduced. Interestingly, CMA activation rescued these changes,
suggesting the therapeutic potential of this approach.
Mechanisms Through Which LRRK2
Regulates Autophagy
Over the years, different pathways have been identified through
which LRRK2 modulates autophagy, although in most studies it
is not possible to dissect out direct vs. indirect effects (Figure 2).
LRRK2 might operate through various subsets of Rab GTPases,
since Rab3A/B/C/D, Rab8A/B, Rab10, Rab12, Rab29, Rab35 and
Rab43 are LRRK2 substrates (Ito et al., 2016; Steger et al., 2016,
2017) and the Rab GTPase network has been implicated in
many stages of autophagy (Zoppino et al., 2010; Dou et al.,
2013; Feldmann et al., 2017). Another putative pathway through
which LRRK2 regulates autophagy is the MEK/ERK/Beclin-1
axis. In particular, Bravo-San Pedro et al. (2013) reported that
LRRK2 G2019S increased basal autophagy in fibroblasts and the
effect was reversed by the MAPK1/3 inhibitor UO126. Moreover,
Manzoni et al. (2016) reported that activation of autophagy
following LRRK2 kinase inhibition requires the increase of PI3P
levels operated by the VPS34/Beclin-1 rather than mTOR/ULK1
pathway. Both studies are in line with the findings of Plowey
et al. (2008) who showed that 3-Methyladenine, a PI3K inhibitor
responsible for the mTOR-mediated activation of autophagy,
did not prevent mutant LRRK2-induced neurite shortening,
whereas the MAPK1/3 inhibitor U0126 did. In contrast with
this view, activation of RAW264.7 macrophages or murine BV2
microglial cells via TLR4 caused phosphorylation and membrane
translocation of LRRK2, inducing autophagy via an mTOR-
dependent mechanism (Schapansky et al., 2014). The discrepancy
on which pathway is preferentially recruited by LRRK2 for
activating autophagy might be due to the different cell types
employed. In fact, LRRK2 might exert a different effect on
immune cells compared to other cell lines since immune cells
express high levels of LRRK2 mRNA and protein, which are
further enhanced in case of activation of these cells (Hakimi
et al., 2011; Thevenet et al., 2011). Furthermore, cell activation
and translocation of LRRK2 to the autophagosome membrane
might be relevant for the physiological activity of LRRK2
but not for the pathological mechanisms underlying LRRK2-
associated PD. Finally, work from Hilfiker and collaborators
disclosed a link between calcium homeostasis, LRRK2 and
autophagy (Gomez-Suaga and Hilfiker, 2012; Gomez-Suaga et al.,
2012a,b). It is well known that cytosolic calcium regulates
autophagy at different levels (Bootman et al., 2018). These
authors reported that overexpression of LRRK2 or the G2019S
mutant in cell lines increases the autophagosome number
through an mTOR-insensitive, LRRK2 kinase-sensitive pathway
(Gomez-Suaga et al., 2012b). The LRRK2 effect relied on Ca2+
release from ER and CaMKK/AMPK pathway activation, and
was mimicked by the Ca2+ mobilizing compound nicotinic
acid adenine nucleotide diphosphate (NAADP), acting via
endolysosomal two-pore channels (TPCs). Interestingly, LRRK2
effect was occluded by an inactive mutant of TPC type 2
(TPC2) and by a pharmacological TPC2 inhibitor. Since TPC2
are expressed by lysosomes, it was proposed that LRRK2
causes the opening of TPC2 and Ca2+ release from lysosomes,
which triggers further Ca2+ release from ER and induces
autophagy via CaMKK/AMPK (Gomez-Suaga and Hilfiker,
2012). It remains to be established whether TPC2 opening is
mediated by a direct interaction with LRRK2 or a recruitment of
Rabs (e.g., Rab7).
LRRK2 seems also to play a significant role on more
specific subtypes of autophagy, namely mitophagy and CMA.
A link between LRRK2 and mitophagy was early suggested
by two studies that showed the presence of TOM20, LC3
and active LRRK2 in the same iodixanol gradient membrane
fraction of RAW264.7 macrophages and BV2 microglial
cells (Schapansky et al., 2014). Moreover, pharmacological
inhibition of LRRK2 kinase activity induced Drp-1 mediated
mitochondrial fission in SH-SY5Y cells (Saez-Atienzar et al.,
2014). More recently, Bonello et al. (2019) demonstrated that
G2019S LRRK2 impairs PINK1/Parkin-mediated autophagy
in human fibroblasts, and that LRRK2 kinase activity is
instrumental to this effect. However, this process does not
seem to be directly mediated by LRRK2 but rather by
the interaction with Rab10. In normal conditions, Rab10
accumulates on depolarized mitochondria through the
interaction with PINK1 and Parkin. Here, Rab10 binds
to the autophagy receptor optineurin and promotes its
accumulation and exposition, facilitating the degradation
of depolarized mitochondria. LRRK2, in its physiological
state and more prominently in the presence of kinase-
enhancing mutations, phosphorylates Rab10 at the Thr73
residue, preventing its accumulation and thus inhibiting
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FIGURE 2 | Putative pathways through which LRRK2 modulates autophagy. (1) Overexpression of LRRK2 or its mutants inhibits CMA through blockade of the
translocation into the lysosome operated by the LAMP2A receptor (Orenstein et al., 2013). Furthermore, LRRK2 is able to modulate autophagy by activating either
(2) the MEK/ERK (Bravo-San Pedro et al., 2013), or the (3) VPS34/Beclin1 complex (Manzoni et al., 2016). Other putative pathways are (4) the mTORC1 pathway
(Imai et al., 2008; Ho et al., 2018), or (8) the Ca2+/CaMKK/AMPK pathway (Gomez-Suaga et al., 2012b). As for mitophagy (5), LRRK2, via Rab activation (Wauters
et al., 2019), is able to disrupt the (6) PINK1/Parkin-mediated mitophagy (Saez-Atienzar et al., 2014; Schapansky et al., 2014; Yakhine-Diop et al., 2014; Bonello
et al., 2019). Furthermore, LRRK2 can regulate lysosomal pH via (7) lysosomal H+-ATPase pump (Wallings et al., 2019). Asterisk (∗) indicates the putative pathways
modulated by pharmacological LRRK2 kinase inhibitors.
mitophagy (Wauters et al., 2019). Furthermore, such LRRK2-
mediated inhibition of mitophagy makes the cell more
susceptible to mitochondrial damage and subsequent cell
death (Yakhine-Diop et al., 2014). A direct link between
LRRK2 and lysosomal activity was recently pointed out by
Wallings et al. (2019), showing that hWT LRRK2 interacts
with the a1 subunit of the v-type H+ ATPase proton
pump (vATPase a1). This pump regulates the acidity of the
lysosomal lumen, which is crucial for the activity of lysosomal
enzymes. Primary cortical neurons obtained from LRRK2
R1441C mice showed decreased binding and protein levels
of vATPase a1, with a significant more basic lysosomal pH,
leading to inhibition of the lysosomal degradation activity
(Wallings et al., 2019).
Regarding CMA, similar to α-syn (Cuervo et al., 2004),
LRRK2 bears different KFERQ peptide motifs in its amino
acid sequence that can be targeted by hsc70. Furthermore,
high levels of WT or LRRK2 mutants inhibit the formation of
the CMA translocation complex at the lysosomal membrane,
thus blocking CMA (Orenstein et al., 2013). The LRRK2-
mediated blockage of CMA induces a compensatory increase
in LAMP2A and accumulation of other CMA substrates,
such as α-syn (Orenstein et al., 2013). The observation
that also high levels or aberrant forms of α-syn inhibits
CMA (Cuervo et al., 2004), strongly points toward a
synergistic role of these two proteins in neurotoxicity
and protein aggregation, which has been a hot topic in
the last few years.
ARE ALP CHANGES OBSERVED IN
LRRK2 MODELS RELEVANT FOR
LRRK2-INDUCED
NEURODEGENERATION?
In vitro studies have demonstrated that not just the G2019S
but also the less common LRRK2 pathogenic mutants are
associated with enhanced kinase activity (Zhao and Dzamko,
2019), and that LRRK2 kinase activity is instrumental to LRRK2-
mediated toxicity (West et al., 2005; Greggio et al., 2006; Plowey
et al., 2008; Yao et al., 2010). On this basis, LRRK2 kinase
inhibitors are being investigated as disease-modifying agents in
models of LRRK2-associated and idiopathic PD (West, 2017;
Zhao and Dzamko, 2019). Therefore, investigating if and to
which extent the neuroprotective effect of LRRK2 inhibitors is
mediated through the modulation of ALP is of great relevance
and translational potential.
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It was originally suggested that autophagy dysregulation
contributes to the LRRK2-associated neurotoxicity in vitro,
since removal of key autophagic proteins LC3 or ATG7
prevented G2019S-associated neurite shortening in SH-SY5Y
cells, whereas autophagy activation by rapamycin worsened
it (Plowey et al., 2008). In other studies, autophagy or CMA
activation was shown to be protective against LRRK2-associated
toxicity. In fact, rapamycin rescued the increase of cell death
triggered by an UPS inhibitor in G2019S-overexpressing
HEK293T cells (Gomez-Suaga et al., 2012b). Likewise, CMA
activation rescued the impairment of lysosomal activity,
the reduction of LAMP2A levels and the accompanying
increase of α-syn in mouse embryonic fibroblasts and primary
neurons obtained from R1441G KI mice (Ho et al., 2019),
although whether these effects made cells more resistant to
parkinsonian toxins was not reported. Consistent with the
view that autophagy blockade leads to neurodegeneration
(Hara et al., 2006; Komatsu et al., 2006b), Wade-Martins
and collaborators reported that the autophagy inhibitor
bafilomycin A1 caused cell death under starvation conditions in
HEK293T cells (Alegre-Abarrategui et al., 2009). In this process,
LRRK2 plays a role since LRRK2 knock-down was protective
(Alegre-Abarrategui et al., 2009).
Only a few studies specifically addressed whether LRRK2
kinase inhibitors modulate ALP in vitro, unfortunately leading
to opposite conclusions. Manzoni et al. (2013a) demonstrated
that LRRK2 inhibitors LRRK2-IN1, GSK2578215A and CZC-
25146 increase the autophagic flux via an mTORC1-independent
pathway, either acting via the Beclin-1 or directly impacting on
ULK1 (Manzoni et al., 2016, 2018). Consistent with induction
of autophagy, GSK2578215A elevated LC3II and reduced p62
levels in bone-marrow-derived macrophages, although the
increase of LC3II levels was minimally affected by bafilomycin
A1, leading the authors to hypothesize that such increase
was not related to autophagic flux changes (Hartlova et al.,
2018). These studies would suggest that blocking LRRK2
kinase activity improves the proteolytic events and helps
cope with misfolded proteins and damaged organelles that
can drive cell death. Consistently, Schapansky et al. (2018)
reported that LRRK2-IN-1 and CZC25146 reversed the lysosomal
changes and reduced the accumulation of detergent-insoluble
α-syn observed in primary cortical neurons obtained from
G2019S KI mice. Moreover, Bonello et al. (2019) showed
that GSK2578215A and LRRK2-IN-1 were able to reverse
the impairment of PINK1/parkin-mediated mitophagy induced
by the G2019S LRRK2 mutation. In contrast with these
studies, Galindo and collaborators showed that nanomolar
(i.e., LRRK2 specific) concentrations of GSK2578215A impaired
the autophagic flux by altering the autophagosome/lysosome
fusion, which led to mitophagy, mitochondrial fission and
cytotoxicity (Saez-Atienzar et al., 2014). A reduction of the
autophagic flux following LRRK2 pharmacological blockade
with LRRK2-IN-1 and GSK2578215A was also observed in
microglial and monocytic cells, which was associated with
an impairment in clearance of Q74 protein aggregates in
microglial cells (Schapansky et al., 2014). The reasons why these
two sets of studies reached opposite conclusions is unclear,
and might depend on cell models and protocols adopted. In
addition, first generation LRRK2 inhibitors were used in these
studies. Major limitation was also that none of these studies
was designed to investigate whether LRRK2 inhibitors were
neuroprotective.
In vivo studies did not help solve the issue. In fact, studies
proving that dysregulation of autophagy is instrumental to
the LRRK2-associated synucleinopathy in vivo are lacking.
This is in part due to the general difficulty in reproducing
a parkinsonian phenotype in LRRK2 KO, KI or transgenic
mice (Volta and Melrose, 2017). In fact, genetic deletion
of LRRK2 is not associated with nigrostriatal DA neuron
degeneration whereas overexpression of hG2019S or hR1441C/G
LRRK2 is inconsistently associated with late-onset nigrostriatal
degeneration (Volta and Melrose, 2017). G2019S KI mice
also do not show overt nigrostriatal neurodegeneration (Volta
and Melrose, 2017), although functional and morphological
changes at dopaminergic synapses and alterations of DA
release have been reported along with aging, which might
represent early sign of neuronal demise or susceptibility
factors to parkinsonism (Yue et al., 2015; Longo et al., 2017;
Novello et al., 2018).
Consistently, when these mice are exposed to parkinsonian
toxins, they do show enhanced susceptibility to nigrostriatal
degeneration. Thus, Daher et al. (2015) reported that G2019S
transgenic rats were more prone than wild-type rats to
develop nigrostriatal dopaminergic degeneration after AAV-
mediated α-syn overexpression, whereas Karuppagounder
et al. (2016) showed that G2019S transgenic mice were more
sensitive to acute MPTP toxicity. Interestingly, subchronic
administration of the second-generation LRRK2 kinase inhibitor
PF-06447475 (West, 2017) reversed the neurotoxicity of α-syn
overexpression not only in G2019S transgenic but also in
wild-type rats. Although, the authors did not investigate whether
this effect was due to a reduced α-syn burden mediated by
an increase of the proteolytic events, this study revealed that
pharmacological LRRK2 kinase inhibition could represent an
appealing therapeutic approach also to idiopathic PD. This
was confirmed by Greenamyre and collaborators who reported
that repeated rotenone administration caused pSer1292 LRRK2
phosphorylation (index of LRRK2 activation) and pSer129
α-syn accumulation (possible early index of neurotoxicity)
in SNc neurons, along with loss of nigrostriatal DA neurons
which were reversed by systemic administration of the third-
generation (West, 2017) LRRK2 inhibitor PF-360 (Di Maio
et al., 2018; Rocha et al., 2019). Conversely, Henderson et al.
(2019) failed to observe neuroprotection and clearance of α-syn
aggregates in naïve mice injected with α-syn preformed fibrils
(PFF), and chronically administered with the potent third-
generation LRRK2 kinase inhibitor MLi-2. This would suggest
that the contribution of LRRK2 to nigrostriatal degeneration
might depend on the neurotoxicity pathways recruited in a
specific experimental model of PD. Despite the role of LRRK2
inhibitor in idiopathic PD remains to be firmly established,
these models offer the opportunity to elucidate whether ALP
modulation contributes to the neuroprotection provided by
LRRK2 inhibitors.
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It is important to notice that these studies were performed in
young-adult (i.e., 3-month-old) mice. Aged animals, however,
might represent a more appropriate model to investigate the
contribution of ALP to LRRK2-induced neurodegeneration.
Indeed, aging is associated with autophagy and CMA
impairment, and in vivo studies suggest that aging facilitates
LRRK2-induced neurodegeneration. In fact, some studies
in hG2019S and hR1441C transgenic mice reported a 18–
50% loss of nigral DA neurons at old ages (16–21 months)
(Ramonet et al., 2011; Chen et al., 2012; Weng et al., 2016)
which were associated with morphological changes of AV
and autophagosomes, reminiscent of ALP impairment
(Ramonet et al., 2011). The view that aging might facilitate
the onset of G2019S LRRK2 neurotoxicity might be further
corroborated by the finding that virus-mediated overexpression
of hG2019S LRRK2 in the striatum of C57BL/6J mice caused
marked neuroinflammation associated with striatal cell loss
(but not dopaminergic terminal loss) in 19-month-old but
not 9–10-week-old mice (Kritzinger et al., 2018). Although
quantification of these changes was not provided, qualitative
analysis of microphotographs revealed that p62 accumulation
was greater in aged mice, suggesting that impairment of
autophagy might play a role in the underlying neurotoxic
mechanisms. Changes in ALP markers (increase in LC3 puncta)
were also observed in old BAC G2019S and BAC R1441C
mice in the absence of overt neurodegeneration, suggesting
that changes in ALP might precede neurodegeneration
(Wallings et al., 2019).
Studies in G2019S KI mice carried out by Morari and
collaborators pointed out an increase of α-syn pSer129 levels
in the striatum and SNpc at 12 months but not earlier ages
(Longo et al., 2017; Novello et al., 2018). Despite the α-
syn signal is due to soluble forms of α-syn (Novello et al.,
2018), it might reflect changes in proteostasis, and particularly
a reduction of autophagic flux due to G2019S mutation
(Schapansky et al., 2018). Consistently, when injected with an
AAV2/9 overexpressing human A53T α-syn under the synapsin
I promoter (Bourdenx et al., 2015; Arcuri et al., 2016), the
aged animals showed a greater reduction of nigral DA neurons
associated with greater accumulation of insoluble, PK-resistant α-
syn and pSer129 α-syn aggregates in SNpc (Novello et al., 2018).
This might reflect a reduced ability of old G2019S KI animals
to cope with α-syn overload, as shown in old nematodes (Saha
et al., 2015). LRRK2 mutations and aging will therefore work
synergistically to inhibit ALP and, consequently, α-syn clearance,
thereby facilitating disease progression and spreading; in this
respect impaired autophagy has been viewed as an “aggravator”
of PD (Johnson et al., 2019). These in vivo studies would
therefore provide a rationale for pharmacological inhibition of
LRRK2 kinase activity both in relation to neuroprotection and
autophagy modulation.
We should also mention the careful in vivo work done by
Giaime et al. (2017), showing that, different from LRRK2 or
LRRK1 KO mice, DKO mice develop age-dependent DA neuron
loss and ALP changes, which became significant at 14–15 months
of age. Lack of both LRRK proteins also affected the viability of
noradrenergic cells in locus coeruleus noradrenergic and striatal
GABAergic medium-sized spiny neurons, and was associated
with elevation of α-syn levels in striatum. Since changes in ALP
markers preceded neuronal loss, these authors proposed that
impairment of autophagy was instrumental to neurodegeneration
(Giaime et al., 2017).
Finally, the role of impaired autophagy/CMA in PD may go
beyond α-syn clearance, and changes in ALP might play a wider
role in PD than hitherto imagined. Indeed, autophagy is active
not only at the soma but also at the synaptic terminals, where
it regulates synaptic protein quality control and synaptic activity
(Hernandez et al., 2012; Vijayan and Verstreken, 2017). Soukup
et al. (2016) have shown that protein quality control at synapses of
Drosophila melanogaster is mediated by EndophilinA, a protein
enriched in phagophore membranes, which is phosphorylated
by LRRK2. LRRK2 phosphorylation allows the protein to create
curved membranes that can harbor and recruit ATG3 to initiate
autophagy (Soukup et al., 2016). Therefore, derangement of
synaptic autophagy can affect synaptic homeostasis and plasticity
which may increase the susceptibility to PD in the long term
(Soukup et al., 2016, 2018; Vijayan and Verstreken, 2017).
CONCLUSION AND PERSPECTIVES
Autophagy is a key mechanism through which cells operate
protein quality control and respond to environmental challenges.
Autophagy activation can prolong the life-span of invertebrates
and rodents, whereas impairment of autophagy leads to a number
of disorders, among which neurodegenerative disorders of aging.
A close association between autophagy and neurodegeneration
has been established, although the casual link remains to be
proven. In PD, ALP impairment can lead to increased levels of
misfolded α-syn, accelerating its transport and spread throughout
the brain. Aging, the major risk factor in PD, might facilitate
this process since the efficiency of ALP machinery worsens over
time. Genetic risk factors of PD, such as LRRK2 mutations, also
impact on autophagy, although the control operated by LRRK2
and its mutants on ALP machinery is far from clear. In vitro
studies offer evidence that G2019S LRRK2 causes autophagy and
CMA impairment, and that autophagy activation rescues LRRK2-
associated cell death or toxicity. Unfortunately, ALP changes
measured in LRRK2 KO, KD and LRRK2 mutant transgenic
mice are inconsistent, perhaps due the intrinsic complexity of
the network through which LRRK2 controls autophagy, and the
lack of standardized protocols to study autophagic flux in vivo.
Furthermore, data obtained in transgenic mice should be taken
with caution due to the obvious limitations of the models (e.g.,
non physiological expression levels of LRRK2, coexistence of
endogenous and mutant LRRK2, neuronal pattern of LRRK2
expression). Finally, the lack of solid, progressive in vivo
models of LRRK2-associated synucleinopathy has hindered the
comprehension of the role of autophagy in LRRK2-associated
parkinsonism, and discouraged the testing of potential disease-
modifying agents, among which LRRK2 kinase inhibitors. The
identification of early markers of neuronal demise in LRRK2
mice, among which alterations in presynaptic autophagy, will
offer new opportunities for pharmacological intervention.
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